Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 13/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14778943 | 0.93 | PKM (0.50) | PKMCA9NPC1MAPK13MAPK12 | |
| SCHEMBL19278654 | 0.85 | CA9 (0.52) | PKMCA9NPC1MAPK13MAPK12 | |
| SCHEMBL12559817 | 0.79 | PKM (0.56) | PKMCA9NPC1MAPK13MAPK12 | |
| SCHEMBL19260285 | 0.79 | PKM (0.56) | PKMCA9NPC1MAPK13MAPK12 | |
| SCHEMBL12992058 | 0.79 | CA9 (0.54) | PKMCA9NPC1MAPK13MAPK12 | |
| SCHEMBL18112918 | 0.79 | CA9 (0.46) | PKMCA9NPC1MAPK13MAPK12 | |
| SCHEMBL10570246 | 0.79 | CYP19A1 (0.51) | PKMCA9NPC1MAPK13MAPK12 | |
| SCHEMBL4609019 | 0.78 | KIF11 (0.57) | PKMNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL16050307 | 0.76 | AHR (0.53) | MAOBCMA1AHR | |
| SCHEMBL7377454 | 0.75 | CA9 (0.54) | PKMCA9NPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299262-A1 | ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | EPIGENETIX, INC. | 2020-09-24 | — | — | US | disclosed |
| EP-3334717-B1 | ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | NEOMED INST (CA) | 2020-07-01 | — | — | EP | disclosed |
| EP-3334717-B1 | ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | NEOMED INST (CA) | 2020-07-01 | — | — | EP | disclosed |
| WO-2017024408-A1 | ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | NEOMED INSTITUTE (CA) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299262-A1 | ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BRPF3, BRD4, BRDT | PKM 2752/4885CA9 4195/4885NPC1 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.